Endoxifen Hydrochloride
Phase 2Small molecule
Endoxifen Hydrochloride is one of 5 small molecule programs targeting Recurrent Breast Carcinoma. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Breast Carcinoma in Situ
#DrugCompanyPhaseTrials
1Aromasin
PfizerApproved
Keytruda
Merck & Co.Phase 3
Tykerb
NovartisPreclinical
Endoxifen Hydrochloride
NNational Cancer Institute (NCI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Carcinoma in Situ1 trial
Recurrent Breast Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Endoxifen Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)